A grant termination is a specific legal action: a federal awarding agency or a recipient institution ending an active award before its scheduled end date. It is not the same thing as a grant simply running out, and it is not the same thing as a competing renewal application failing to get funded. For NIH awards specifically, termination is governed by the Uniform Guidance at 2 CFR Part 200, Subpart D — the same regulation that governs cost principles and audit requirements across all US federal research funding — and by NIH’s own implementation of that regulation in the NIH Grants Policy Statement. This guide covers the actual mechanism: the grounds on which NIH can terminate an award, how notice and objection work, what distinguishes termination from non-renewal or ordinary expiration, and how the well-publicized 2025–2026 wave of NIH terminations fits into (and in some respects tested) that underlying framework.
The Legal Basis: 2 CFR 200.340
2 CFR 200.340 sets out the grounds on which a federal awarding agency (or, for a subaward, a pass-through entity) may terminate a federal award, in whole or in part, before the end of the period of performance:
- Non-compliance – 200.340(a)(1). The recipient or subrecipient fails to comply with the terms and conditions of the award, including applicable statutes, regulations, or the terms of the award document itself.
- Mutual agreement – 200.340(a)(2). The agency and the recipient agree to terminate, with the two parties agreeing on the termination conditions, including the effective date and, where the award is only partially terminated, the portion affected.
- Recipient-initiated termination – 200.340(a)(3). The recipient itself decides to terminate the award (or a portion of it) and gives the agency written notification of its reasons, and, where a subaward is involved, the effective date. The agency may terminate the entire award if it determines the remaining portion will not accomplish the purposes for which it was made.
- Award no longer effectuates agency priorities – 200.340(a)(4). The agency may terminate an award, to the extent authorized by law, if it determines that the award no longer effectuates the program goals or agency priorities. This is the most consequential ground for the current NIH termination environment discussed below — it does not require a compliance failure on the recipient’s part.
Two companion sections govern the mechanics around any 200.340 action. 2 CFR 200.341 is the notification requirement: an agency terminating an award must give the recipient written notice of the termination, and in practice that notice states the effective date, the specific ground relied on, and (for a partial termination) which portion of the award is affected. 2 CFR 200.342 is the recipient’s procedural protection: before termination or another compliance remedy takes effect, the agency must give the recipient an opportunity to object and provide information challenging the action, and the agency must comply with any hearing, appeal, or other administrative-proceeding rights the recipient is separately entitled to under applicable statute or regulation — which, for HHS/NIH awards, means the appeal procedure described below.
How NIH Implements Termination
NIH does not operate an independent termination regulation of its own — it applies 2 CFR 200.340–200.342 through its Grants Policy Statement (NIH GPS), and communicates a termination action through a revised Notice of Award that states the ground relied upon and the new project end date. Institutions receiving a termination notice generally move immediately into an accelerated closeout process rather than the standard end-of-project closeout timeline.
Termination vs. Non-Renewal vs. Expiration
These three outcomes are frequently conflated in casual usage but are legally and procedurally distinct, and the distinction matters for what rights and next steps apply:
- Termination ends an active, currently-funded award before its scheduled end date, under one of the 200.340 grounds above. It is an affirmative action by the agency or recipient, not a passive lapse.
- Non-renewal is a decision not to fund a new, competing award — typically a competing renewal (Type 2) application for a project that already received a prior segment of funding. The prior segment simply runs its course and closes out normally; nothing is terminated early, because there was nothing left to terminate once the new application wasn’t funded. This is a continuation decision a study section and program officer make going forward, not a termination of the award already in hand.
- Expiration is the ordinary end of a project period on its originally scheduled date (or an approved extended date, following a no-cost extension). Expiration triggers routine closeout — final financial and progress reporting on the normal timeline — not the accelerated closeout and objection rights that attach to a termination.
A related but distinct remedy is suspension, which temporarily halts an award (and typically the recipient’s authority to draw down funds) without ending it, usually pending resolution of a compliance concern that may or may not eventually lead to termination.
Notice, Objection, and Appeal Rights
Because 2 CFR 200.342 requires HHS to honor any separate statutory or regulatory hearing/appeal rights a recipient has, NIH terminations carry a defined appeal path. Under the NIH Grants Policy Statement’s grant appeals procedures, a recipient generally must first pursue NIH’s own first-level internal grant appeal before going further. NIH itself has jurisdiction to decide appeals of terminations for failure to carry out the approved project in accordance with law and the award’s terms and conditions. If the outcome of that internal NIH review is adverse to the recipient, the recipient may then request further review from the HHS Departmental Appeals Board (DAB) under 45 CFR Part 16, generally by filing a notice of appeal within 30 days of the final NIH decision. The DAB process is designed to be faster and less formal than federal court litigation, though it is still a real adversarial proceeding with a written record and a final, reviewable decision.
This internal appeal path is separate from, and does not preclude, a recipient’s ability to separately challenge the underlying legality of an agency policy or directive in federal court — a distinction that became directly relevant in the 2025 litigation discussed next.
The 2025–2026 NIH Termination Wave: Real-World Context
The 200.340(a)(4) “agency priorities” ground is not a hypothetical — it is the provision at the center of a large, well-documented wave of NIH grant terminations that began in 2025, principally affecting awards NIH characterized as related to diversity, equity, and inclusion (DEI) topics and, separately, gender-identity research. Affected institutions and researchers, joined by public-health organizations, challenged the terminations in federal court. In June 2025, a federal district judge in Massachusetts ruled that the underlying NIH directives and the resulting terminations were unlawful under the Administrative Procedure Act and issued a partial final judgment vacating them. The government appealed, and the Supreme Court intervened in August 2025: in a 5–4 order, the Court left in place the part of the district court’s ruling that vacated the NIH policy directives themselves, but held that the district court likely lacked jurisdiction to review the termination of the individual grants — indicating that challenges to specific grant terminations belong instead in the Court of Federal Claims, a different forum with a different procedural posture, rather than in district court alongside a broader policy challenge. As of this writing, the litigation continues on that bifurcated track: policy-level challenges in district court (on appeal to the First Circuit, which heard oral argument in January 2026) and claims over specific terminated awards proceeding, where pursued, in the Court of Federal Claims.
The practical point for a research administrator is not the outcome of any single case — that is still moving — but that the 2025–2026 wave is best understood as a large-scale, court-contested application of an existing regulatory ground (200.340(a)(4)) rather than a new or separate termination mechanism. The underlying process described above — written notice, an opportunity to object, and the NIH/DAB appeal path — is the same process that applies to any NIH termination, whether it is one of these high-profile cases or an isolated non-compliance termination on an unrelated award. Institutions navigating an active or anticipated termination should treat the litigation as evolving context, and confirm current guidance directly with NIH’s Office of Extramural Research or institutional legal counsel rather than relying on a static summary of a fast-moving docket.
What Happens After a Termination: Closeout Obligations
A termination does not erase the recipient’s existing obligations on funds already drawn down or committed. In practice, a terminated award moves into an accelerated version of standard closeout: the recipient generally must submit final financial and progress/technical reports on an expedited timeline, return any unobligated federal funds, and resolve outstanding subaward and subcontract obligations, since a prime recipient’s termination generally flows down to affect subrecipients as well. A termination for cause (the 200.340(a)(1) non-compliance ground) can also affect the recipient’s standing on future funding applications and may be a reportable event under an institution’s own risk and compliance procedures, distinct from formal debarment, which is a separate, more severe government-wide exclusion action.
Frequently Asked Questions
Can NIH terminate a grant without any compliance failure by the recipient?
Yes. 2 CFR 200.340(a)(4) allows an agency to terminate an award if it determines the award no longer effectuates program goals or agency priorities, independent of whether the recipient did anything wrong. This is distinct from the non-compliance ground at 200.340(a)(1) and is the provision underlying most of the 2025–2026 NIH terminations described above.
What is the difference between a grant being terminated and a grant simply not being renewed?
Termination ends an active award early. Non-renewal means a new competing application for continued funding was not selected — the prior award simply runs to its own scheduled end and closes out normally, because there is no active award being cut short.
Can a recipient appeal an NIH grant termination?
Yes, through a defined path: 2 CFR 200.342 guarantees an opportunity to object before termination takes effect, and NIH’s own grant appeals procedures provide a first-level internal NIH review, with further review available from the HHS Departmental Appeals Board under 45 CFR Part 16 if the NIH-level decision is adverse.
Does terminating a grant mean the institution has to return all the money it already received?
Not all of it, but termination does trigger accelerated closeout obligations, including return of any unobligated (unspent, uncommitted) federal funds. Costs already properly incurred in accordance with the award’s terms before termination are generally treated differently from funds that were drawn down but not yet obligated.
Is a suspended grant the same as a terminated one?
No. Suspension temporarily halts an award, typically pending resolution of a concern, without ending it. Termination is a final action ending the award (or a defined portion of it) before its scheduled end date.
